(IN BRIEF) Scientists at The Institute of Cancer Research in London have made significant strides in understanding why some cases of neuroblastoma—a pediatric cancer of nerve tissue—result in poorer outcomes. Their research indicates that mutations in the ATRX gene, which … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ATRX gene, Cancer Letters, Cancer Research UK, Dr Sally George, Federica Lorenzi, high-risk, immune cell infiltration, inflammatory pathways, macrophages, MYCN gene amplification, Neuroblastoma, Neuroblastoma UK, paediatric oncology, personalised therapy, targeted treatment, The Institute of Cancer Research, TIME, tumour immune microenvironment
(IN BRIEF) Researchers at the Technical University of Munich (TUM) have developed an inhalable RNA-based drug that targets macrophages, overactive immune cells often responsible for lung damage in diseases like Covid-19. The drug, RCS-21, inhibits the activity of microRNA 21, … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Christina Beck, Inhalable, macrophages, medicine, microRNA 21, pneumonia, RCS-21, RNA Drug, RNATICS, Severe Lung Inflammation, Stefan Engelhardt, Technical University of Munich, trimannose, wellness
Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating COVID-19 in addition to other diseases for which no therapeutic solutions are available (PRESS RELEASE) PARIS, 30-Nov-2020 — /EuropaWire/ — … Read the full press release
Posted in Banks, European Union, Financial, France, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Small Business
Tagged 3CL protease, AB Science SA, Alain Moussy, Ambroise Fayolle, anti-inflammatory, antiviral, chemotherapy, COVID-19, COVID-19 treatment, EIB, European Commission, European Fund for Strategic Investments, European Investment Bank, European Union, financing, health crisis, Horizon 2020, immunotherapeutic, inflammatory disease, innovationm, InnovFin, investments, kinase inhibitors, kinases, loan, macrophages, masitinib, microglia, neurological diseases, oncology, PKIs, RESEARCH, SARS-CoV-2, tyrosine kinase inhibitor
New work by LMU researchers demonstrates that macrophages can effectively substitute for so-called dendritic cells as primers of T-cell-dependent immune responses. Indeed, they stimulate a broader-based response. München, 16-4-2015 — /EuropaWire/ — The immune response, the process by which the … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?